Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Guselkumab
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[6] 37, 41, 96, 97, 161, 269 💬
2Guselkumab 100 MG
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 37 💬
3Guselkumab dose 1
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[3] 51, 96, 97 💬
4Guselkumab dose 2
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[3] 51, 96, 97 💬
5Guselkumab dose 3
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
6Guselkumab dose 4
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
7Guselkumab dose 5
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
8Guselkumab intravenous
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 97 💬
9Guselkumab subcutaneous
(Tremfya, TREMFYA)		[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 97 💬
10Tremfya[1] Guselkumab[1] Guselkumab (Tremfya, TREMFYA) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 37 💬